Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy

The advent of checkpoint inhibitor immunotherapy has rapidly changed the landscape of the management of cancers. However, its use has also been associated with the rise of immunotherapy-related adverse effects (irAEs). There has been an emergence in recent years of sclerosing cholangitis as a mimic of the classical autoimmune hepatitis irAE. We present a case of a 59-year-old female who received pembrolizumab for stage IV lung adenocarcinoma and developed an immune checkpoint inhibitor (ICI) related sclerosing cholangitis diagnosed on radiological and histopathological grounds. This patient was successfully treated with prednisone, azathioprine, and ursodeoxycholic acid. Clinicians should be aware that ICI sclerosing cholangitis is a rare hepatic complication of ICIs. The workup for ICI-associated mixed liver function test derangement that is steroid resistant should include a magnetic resonance cholangiopancreatography to investigate for changes of sclerosing cholangitis and a liver biopsy if the magnetic resonance cholangiopancreatography is nondiagnostic.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy ; volume:16 ; number:1 ; year:2023 ; pages:188-193 ; extent:6
Case reports in oncology ; 16, Heft 1 (2023), 188-193 (gesamt 6)

Creator
Liang, Ian
Chu, Geoffrey
Zielinski, Robert

DOI
10.1159/000530009
URN
urn:nbn:de:101:1-2023122723414805466784
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Associated

  • Liang, Ian
  • Chu, Geoffrey
  • Zielinski, Robert

Other Objects (12)